GlassScriptPhysician profile
Laura M Hubbard
NPI 1457450249
$5,389.60
in general payments reported to CMS, 2019-2025
45 companies · $1,079 in 2025
The $1,079 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $968 · 2020: $385 · 2021: $469 · 2022: $583 · 2023: $926 · 2024: $980 · 2025: $1,079.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,985.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,984.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $758.01 | 2021-2025 | |
| Novo Nordisk INC | $667.09 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $470.76 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $461.60 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $357.89 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $325.97 | 2019-2023 | Jardiance |
| Pfizer INC. | $247.68 | 2019-2024 | |
| Paratek Pharmaceuticals, INC. | $146.28 | 2023-2025 | Nuzyra |
| Bayer Healthcare Pharmaceuticals INC. | $140.46 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $137.66 | 2019-2023 | Xarelto |
| Phathom Pharmaceuticals, INC. | $133.58 | 2024-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $118.93 | 2023-2025 | Rexulti |
| Mylan Specialty L.P. | $111.56 | 2019-2024 | Yupelri |
| Sunovion Pharmaceuticals INC. | $97.31 | 2021-2022 | |
| Amgen INC. | $95.08 | 2024-2025 | Repatha, Repatha, Otezla |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Hubbard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.